Professor

Dr. Ha Rin Kim earned her B.S. in Pharmacy and pursued her M.Sc. and Ph.D. focusing on peptide-drug conjugate delivery systems and cancer immunotherapy. During her postdoctoral fellowship, she further specialized in mRNA cancer vaccines, utilizing the charge-altering releasable transporter (CART) system.

Dr. Kim’s current research focuses on developing mRNA-based anti-cancer vaccines, in vivo CAR-T therapies, and nanoparticle delivery systems that precisely target immune cells. Her work is dedicated to reshaping the immune microenvironment, with a key focus on in vivo antigen-presenting cell engineering to enhance immune responses against cancer. Beyond cancer immunotherapy, her research also extends to modeling the immune microenvironment and exploring innovative therapeutic approaches for inflammatory bowel disease.